Nemes Rush Group’s Denali Therapeutics DNLI Stock Holding History

Nemes Rush Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.5K	Hold	700	–	–	﹤0.01%	514
2026 Q2	$18K	Hold	700	–	–	﹤0.01%	502
2026 Q1	$13.4K	Hold	700	–	–	﹤0.01%	512
2025 Q4	$11.6K	Hold	700	–	–	﹤0.01%	531
2025 Q3	$10.2K	Hold	700	–	–	﹤0.01%	485
2025 Q2	$9.8K	Hold	700	–	–	﹤0.01%	478
2025 Q1	$9.5K	Hold	700	–	–	﹤0.01%	469
2024 Q4	$14.3K	Hold	700	–	–	﹤0.01%	432
2024 Q3	$14.4K	Hold	700	–	–	﹤0.01%	371
2024 Q2	$16.3K	Hold	700	–	–	﹤0.01%	364
2024 Q1	$14.4K	Hold	700	–	–	﹤0.01%	408
2023 Q4	$15K	Hold	700	–	–	﹤0.01%	385
2023 Q3	$14.4K	Hold	700	–	–	﹤0.01%	367
2023 Q2	$20.7K	Buy	+700	New	+$19.7K	﹤0.01%	363

Other funds holding DNLI

Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Nemes Rush Group's DNLI Position: Q3 2026 in Review

Nemes Rush Group held its Denali Therapeutics (DNLI) position steady in Q3 2026 at 700 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #514.

Nemes Rush Group first reported a position in DNLI in Q2 2023 and has held it in 14 quarters since. The position peaked at $20.7K in Q2 2023. 92 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

Nemes Rush Group held 700 shares of Denali Therapeutics worth $14.5K as of Q3 2026.
Nemes Rush Group left its Denali Therapeutics share count unchanged in Q3 2026.
Denali Therapeutics made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #514 holding.
Nemes Rush Group first reported a position in Denali Therapeutics in Q2 2023 and has held it in 14 quarters since.
Nemes Rush Group's Denali Therapeutics position peaked at $20.7K in Q2 2023.
92 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.